IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$3.6b

IDEAYA Biosciences Future Growth

Future criteria checks 2/6

IDEAYA Biosciences is forecast to grow earnings and revenue by 27% and 44.3% per annum respectively. EPS is expected to grow by 26.5% per annum. Return on equity is forecast to be -40.9% in 3 years.

Key information

27.0%

Earnings growth rate

26.54%

EPS growth rate

Biotechs earnings growth28.9%
Revenue growth rate44.3%
Future return on equity-40.90%
Analyst coverage

Good

Last updated10 Sep 2026

Recent future growth updates

Analysis Article • May 08

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...

Recent updates

Analysis Article • Jun 17

IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone

IDEAYA Biosciences (IDYA) stock is in focus after the company enrolled the first patient in a Phase 1 trial that combines IDE892 and IDE397 for MTAP-deleted solid tumors, including pancreatic and non-small cell lung cancers. See our latest analysis for IDEAYA Biosciences. At a share price of $30.57, IDEAYA Biosciences has seen strong short term momentum, with a 7 day share price return of 10.76% and a 30 day share price return of 7.94%. However, the 90 day share price return declined 6.23%,...
Seeking Alpha • Jun 11

Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026

Summary IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company's darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM, supporting an RTOR NDA Accelerated Approval submission filing. Upcoming catalysts include NDA filing submission completion of darovasertib in H2 2026, label expansion data for HLA*A2-positive mUM, and further neoadjuvant/adjuvant melanoma updates. The company boasts a cash runway into 2030, recently raised $300M, and retains U.S. rights plus milestone/royalty upside through its Servier partnership. Read the full article on Seeking Alpha
Analysis Article • Jun 02

News Flash: Analysts Just Made A Substantial Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasts

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 08

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...
Analysis Article • May 07

Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates

Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...
Analysis Article • Jul 28

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 16

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Summary IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of operational liquidity. Strength: Strong liquidity. Risk: Heavy reliance on key data catalysts for future success. Read the full article on Seeking Alpha
Analysis Article • Apr 13

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 10

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Summary Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034. IDYA is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028, reducing near-term dilution risk. Read the full article on Seeking Alpha
Analysis Article • Jan 03

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 04

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Summary Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile. With a market cap of $2.37bn and a cash runway into 2028, IDYA is financially well-positioned, despite the inherent risks of late-stage studies. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Summary IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments. IDE397 shows a 94% disease control rate in Phase 2 trials for MTAP-deleted tumors, with favorable safety and efficacy profiles, positioning it as a potential first-in-class treatment. IDYA has a robust cash runway and reasonable valuation, which is why I rate it a "buy" for long-term biotech investors. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demonstrated positive phase 2 data for MTAP-deleted NSCLC and urothelial cancer. With a solid financial position and potential for accelerated approvals, IDYA presents a compelling investment opportunity, although the current valuation may be high. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet. An updated analysis around Ideaya Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:IDYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028255-368-353-27612
12/31/2027115-421-378-40114
12/31/202639-432-383-35415
6/30/2026234-175-114-112N/A
3/31/2026225-140-88-86N/A
12/31/2025219-114-73-71N/A
9/30/2025215-161-105-102N/A
6/30/20257-332-297-294N/A
3/31/20257-307-268-264N/A
12/31/20247-274-251-248N/A
9/30/20244-178-153-150N/A
6/30/202412-154-134-131N/A
3/31/202416-129-135-131N/A
12/31/202323-113-118-115N/A
9/30/202323-103-116-115N/A
6/30/202345-74-111-109N/A
3/31/202347-68-98-95N/A
12/31/202251-59-91-87N/A
9/30/202250-53-85-80N/A
6/30/202229-66-72-69N/A
3/31/202232-55-64-62N/A
12/31/202128-50-58-56N/A
9/30/202136-37-53-51N/A
6/30/202136-305052N/A
3/31/202127-315051N/A
12/31/202020-345555N/A
9/30/20209-405858N/A
6/30/2020N/A-46-43-42N/A
3/31/2020N/A-44N/A-39N/A
12/31/2019N/A-42N/A-39N/A
9/30/2019N/A-40N/A-38N/A
6/30/2019N/A-42N/A-36N/A
3/31/2019N/A-38N/A-32N/A
12/31/2018N/A-34N/A-28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDYA's revenue (44.3% per year) is forecast to grow faster than the US market (13.4% per year).

High Growth Revenue: IDYA's revenue (44.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IDYA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 01:52
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Zhiqiang ShuBerenberg
Li Wang WatsekCantor Fitzgerald & Co.